Available evidence indicates HIV-infected population promising new approach has emerged. HIV causes an infectious
disease that, with the right prevention interventions delivered within a human rights framework, can be controlled and
possibly even eliminated. WHO, UNAIDS and the United Nations General Assembly have called for 15 million people to be
on ART by 2015. Anti Retroviral Treatment (ART) has considerable benefit, both as treatment and in preventing HIV. Preexposure
prophylaxis (PrEP) is available from studies with two groups: men and transgender women who have sex with men; and
serodiscordant heterosexual couples. Several human clinical trials evaluating the efficacy of daily regimens of the HIV reversetranscriptase
(RT) inhibitors tenofovir disoproxil fumarate (TDF) or Truvada (TDF and emtricitabine [FTC]) are under way
among high-risk populations. The results of one trial among men who have sex with men showed that daily Truvada was safe and
effective, providing the first support for oral PrEP as a prevention strategy. This article summarizes Guidance on pre-exposure
oral prophylaxis (PrEP) for serodiscordant couples, men and transgender women who have sex with men at high risk of HIV.
Rajendar.M is a student of JSS College of Pharmacy, JSS University, Mysore, Karnataka, India. He has completed his B Pharm from JSS College
of Pharmacy, Mysore during the year 2011. Presently he is pursuing M Pharm in Industrial pharmacy in JSS College of Pharmacy, Mysore. He
has attended various National and International Conferences. His current areas of interest are Quality Assurance, Regulatory Affairs, Quality
Management Systems, pharmaceutical technology and analytical method development.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals